sever
fever
thrombocytopenia
syndrom
sft
emerg
infect
caus
novel
bunyaviru
analysi
dynam
chang
clinic
laboratori
immunolog
abnorm
associ
sft
concurr
studi
lack
thirtythre
sft
patient
admit
jiangsu
peopl
hospit
nanj
china
diagnosi
made
base
clinic
symptom
posit
viral
rna
detect
rtpcr
four
patient
deceas
twentynin
surviv
blood
sampl
collect
everi
day
day
day
onset
fever
sampl
healthi
volunt
use
normal
control
peak
viral
rna
load
serum
enzym
significantli
higher
deceas
patient
compar
survivor
viral
load
serum
enzym
cytokin
declin
survivor
within
week
onset
fever
cell
elev
earli
infect
hladr
cell
elev
recoveri
phase
surviv
high
level
sftsv
viral
load
concurr
observ
reduc
plt
elev
serum
enzym
elev
proinflammatori
antiinflammatori
cytokin
activ
cell
degre
pattern
chang
paramet
may
indic
clinic
outcom
sftsvinfect
patient
sever
fever
thrombocytopenia
syndrom
sft
emerg
infecti
diseas
recent
discov
china
caus
agent
ill
sever
fever
thrombocytopenia
syndrom
viru
sftsv
identifi
novel
tickborn
bunynaviru
genu
phleboviru
also
name
huaiyangshan
viru
sinc
origin
case
identifi
huaiyangshan
mountain
report
sftsv
transmit
sever
way
patient
infect
tick
bite
viru
detect
haemaphysali
longicorni
tick
andor
persontoperson
transmiss
via
contact
blood
patient
sft
sporad
cluster
sft
endem
document
least
six
provinc
northeastern
eastern
central
china
sinc
typic
clinic
present
sft
acut
fever
thrombocytopenia
platelet
count
less
addit
nonspecif
featur
includ
muscl
pain
sever
malais
nausea
vomit
diarrhea
high
mortal
rate
rang
report
sftsvinfect
patient
exact
mechan
sftsv
pathogenesi
remain
unclear
gener
suspect
immunopatholog
play
key
role
viral
infect
immun
activ
exagger
cytokin
product
form
cytokin
storm
potenti
drive
sft
diseas
process
sever
studi
report
sftsv
infect
could
lead
elev
level
serum
cytokin
might
contribut
diseas
sever
clinic
outcom
separ
report
shown
viral
infect
induc
cell
popul
chang
howev
almost
previou
report
show
data
collect
one
two
time
point
diseas
process
rather
determin
dynam
chang
key
lab
test
result
immunolog
marker
incur
critic
clinic
period
shortli
infect
current
report
chang
sftsv
viral
load
platelet
white
blood
cell
count
level
key
serum
enzym
cytokin
profil
chang
two
import
subset
popul
measur
everi
day
first
day
hospit
four
deceas
patient
twentynin
survivor
diagnos
sftsv
infect
inform
learn
current
studi
provid
better
understand
relationship
clinic
diseas
progress
key
clinic
lab
immunolog
paramet
inform
also
use
guid
indepth
investig
mechan
sftsv
pathogenesi
may
juli
thirtythre
patient
male
femal
tabl
confirm
sftsv
infect
base
diagnost
guidelin
chines
ministri
health
admit
depart
infecti
diseas
first
affili
hospit
nanj
medic
univers
nanj
china
patient
rural
area
three
eastern
china
provinc
patient
anhui
patient
jiangsu
shandong
geograph
connect
four
patient
die
anhui
jiangsu
addit
sftsvinfect
patient
thirtytwo
healthi
volunt
male
femal
also
enrol
studi
tabl
serv
normal
control
written
inform
consent
obtain
particip
studi
approv
institut
review
board
first
affili
hospit
nanj
medic
univers
sftsvinfect
patient
receiv
standard
antivir
standard
support
treatment
admiss
hospit
base
sft
treatment
guidelin
chines
ministri
health
individu
identif
code
given
particip
blood
sampl
collect
identif
code
sftsvinfect
patient
sampl
collect
hospit
day
onset
fever
blood
sampl
healthi
donor
collect
singl
time
point
time
enrol
blood
cell
platelet
count
measur
japanes
sysmex
fullyautomat
blood
cell
analyz
japanes
olympu
fullyautomat
biochem
detector
use
determin
level
alanin
transaminas
alt
aspart
transaminas
ast
lactic
dehydrogenas
ldh
creatin
kinas
ck
taqman
realtim
fluoresc
quantit
pcr
method
use
detect
sftsv
viral
load
viru
rna
extract
plasma
sampl
use
rna
extract
kit
rtpcr
amplif
conduct
immedi
fluoresc
quantit
pcr
detector
abi
stepon
plu
sftsv
rna
detect
specif
primer
target
highli
conserv
region
sftsv
l
gene
rtpcr
reaction
system
volum
ml
reaction
condit
min
cycl
min
cycl
sec
sec
cycl
fluoresc
signal
collect
fam
channel
lymphocyt
subpopul
cell
activ
profil
patient
pbmc
analyz
flow
cytometri
florescentconjug
cell
surfac
marker
florescentconjug
mous
antihuman
hladrfitc
isotyp
control
mous
mous
bd
bioscienc
ca
usa
cell
popul
analyz
fac
calibur
flow
cytomet
cellquest
softwar
bd
bioscienc
serum
cytokin
detect
use
human
cytometr
bead
array
cba
kit
bd
bioscienc
accord
manufactur
instruct
flow
cytomet
fac
calib
use
detect
tnf
ifnc
level
serum
detect
sensit
cytokin
pgml
result
analyz
use
statist
softwar
window
spp
ibm
compani
mannwhitney
u
nonparametr
test
student
ttest
ranksum
test
appropri
use
compar
mean
valu
two
group
deceas
patient
vs
survivor
infect
group
vs
normal
control
group
consid
statist
signific
period
may
juli
patient
laboratoryconfirm
sftsv
infect
admit
jiangsu
peopl
hospit
nanj
china
patient
share
similar
clinic
manifest
sft
includ
acut
fever
weak
anorexia
nausea
vomit
well
disturb
conscious
ecchymosi
gastrointestin
hemorrhag
critic
condit
tabl
well
hallmark
thrombocytopenia
platelet
count
l
admiss
patient
enrol
studi
confirm
posit
sftsv
blood
sampl
determin
reversetranscriptas
polymeras
chain
reaction
rtpcr
design
primer
sftsv
l
gene
hospit
patient
receiv
similar
treatment
base
guidelin
chines
ministri
health
four
die
within
day
admiss
day
onset
fever
patient
recov
ill
length
symptom
onset
admiss
contribut
mortal
deceas
admit
day
symptom
onset
median
time
admiss
surviv
day
rang
day
tabl
gender
bia
deceas
femal
survivor
femal
patient
hand
median
age
deceas
patient
year
notabl
older
median
age
survivor
year
statist
signific
due
small
sampl
size
tabl
patient
easili
detect
sftsv
blood
sftsv
viral
load
among
survivor
peak
shortli
admiss
within
day
symptom
onset
drop
rapidli
remain
period
studi
fig
contrast
three
four
deceas
patient
admit
day
diseas
onset
die
within
three
day
admiss
much
higher
level
viral
load
one
deceas
patient
similar
level
viral
load
surviv
fig
viral
load
day
group
compar
mean
log
viral
load
deceas
patient
rang
fold
higher
mean
log
viral
load
survivor
rang
fig
indic
namesak
diseas
platelet
plt
count
sftsvinfect
patient
low
diagnosi
made
evidenc
level
half
normal
rang
l
level
drop
ptl
similar
deceas
patient
survivor
fig
patient
admit
hospit
plt
level
improv
steadili
partial
due
treatment
plt
level
return
normal
rang
day
among
survivor
die
day
diseas
onset
low
plt
level
parallel
plt
white
blood
cell
wbc
count
also
normal
rang
l
day
onset
fever
return
normal
around
day
earlier
plt
fig
interestingli
die
wbc
count
within
normal
rang
albeit
lower
end
normal
rang
like
patient
admit
day
slightli
later
mani
patient
wbc
went
admiss
sftsvinfect
patient
acut
tissu
damag
indic
multipl
elev
key
serum
enzym
fig
alt
ast
ck
ldh
highli
elev
deceas
patient
survivor
level
deceas
patient
significantli
higher
survivor
fig
tabl
analysi
demonstr
peak
elev
time
admiss
day
onset
symptom
ast
ck
ldh
level
gradual
declin
among
survivor
alt
level
remain
elev
longer
time
four
patient
die
day
symptom
onset
biomark
highli
elev
suspect
virusinduc
immunopatholog
may
involv
tissu
damag
observ
clinic
present
abnorm
lab
test
chang
import
cell
subset
sftsvinfect
patient
measur
cell
significantli
elev
earli
infect
fig
day
diseas
onset
mean
percentag
cell
survivor
later
deceas
patient
normal
control
group
cell
survivor
later
deceas
patient
normal
control
group
elev
cell
later
deceas
patient
significantli
higher
elev
observ
survivor
p
cell
p
cell
cell
gradual
return
normal
level
survivor
around
week
diseas
onset
hladr
cell
also
measur
fig
deceas
patient
earli
elev
cell
cell
went
later
among
survivor
reach
peak
level
day
diseas
onset
come
although
remain
higher
normal
control
group
contrast
cell
went
time
survivor
deceas
patient
level
continu
go
entir
studi
period
survivor
also
much
higher
observ
normal
control
group
p
cell
show
differ
pattern
cell
went
around
day
diseas
onset
fig
continu
go
higher
observ
normal
control
group
remain
studi
period
deceas
patient
die
around
day
cell
level
significantli
elev
cell
also
measur
signific
differ
observ
sftsvinfect
patient
healthi
donor
data
shown
specif
cytokin
measur
identifi
may
involv
pathogenesi
sft
among
seven
cytokin
measur
studi
signific
differ
tnfa
serum
sampl
sftsvinfect
patient
deceas
survivor
normal
control
group
fig
howev
signific
elev
serum
ifnc
discov
deceas
patient
compar
normal
control
group
also
survivor
fig
survivor
elev
significantli
compar
normal
control
group
fig
tabl
ifnc
actual
lower
survivor
compar
normal
control
group
fig
kinet
three
elev
cytokin
monitor
level
show
upward
trend
deceas
patient
howev
survivor
level
slowli
return
normal
level
fig
ifnc
went
deceas
patient
survivor
sft
mortal
rate
one
sever
emerg
human
infecti
diseas
china
sever
acut
respiratori
syndrom
sar
avian
influenza
new
millennium
previou
studi
document
overal
level
viral
load
chang
key
lab
result
certain
immunolog
biomark
sft
patient
select
time
point
report
concurr
measur
key
abnorm
find
critic
acut
phase
sft
infect
analysi
relat
dynam
chang
sever
cours
diseas
although
thrombocytopenia
key
abnorm
find
sft
level
deceas
patient
survivor
similar
analysi
thu
may
directli
relat
diseas
sever
death
contrast
level
sftsv
viremia
correl
diseas
sever
significantli
higher
level
deceas
patient
survivor
measur
day
onset
fever
viral
load
gradual
drop
among
survivor
recoveri
phase
find
consist
report
sftsv
viral
load
relat
diseas
sever
sftsv
infect
caus
tissu
injuri
organ
damag
lead
elev
serum
enzymat
marker
death
sftsvinfect
patient
alt
ast
ldh
ck
elev
normal
rang
especi
acut
phase
diseas
peak
level
deceas
patient
significantli
higher
survivor
similar
report
hand
kinet
analysi
discov
alt
last
one
come
ast
ldh
ck
start
decreas
among
survivor
earli
admiss
hospit
lab
test
may
serv
great
valu
clinic
prognosi
sftsvinfect
patient
human
immun
system
respond
power
major
viral
infect
sftsv
previou
studi
found
total
cell
total
cell
decreas
sftsvinfect
patient
acut
phase
infect
sever
case
eventu
die
diseas
time
signific
chang
cell
measur
serum
cytokin
sftsvinfect
patient
previou
studi
actual
show
increas
level
consist
cytokin
storm
expect
typic
major
viral
infect
data
total
cell
surpris
current
studi
chang
within
subpopul
cell
investig
profound
cell
activ
discov
three
subset
cell
hladr
found
elev
sftsvinfect
patient
chang
happen
differ
phase
progress
diseas
molecul
human
transmembran
ctype
lectin
protein
cell
earli
activ
marker
cell
elev
acut
phase
sftsv
infect
signific
activ
deceas
patient
compar
survivor
time
point
peak
viremia
cell
subpopul
survivor
gradual
decreas
normal
level
compar
healthi
donor
week
contrast
hladr
mhc
class
ii
cell
surfac
receptor
member
immunoglobulin
superfamili
surfac
helper
cell
cell
elev
recoveri
phase
peak
viremia
survivor
cell
low
measur
acut
phase
infect
deceas
patient
howev
cell
significantli
elev
increas
hladr
cell
often
respons
antigen
bind
signal
cell
bind
antigen
surfac
b
cell
stimul
b
cell
prolifer
tcell
costimulatori
molecul
antigenpres
cell
transmit
inhibitori
signal
cell
hladr
may
serv
upregul
marker
recoveri
phase
may
role
check
rebalanc
lymphocyt
viral
infect
control
taken
togeth
data
impli
increas
cell
may
relat
pathogenesi
late
increas
hladr
cell
may
indic
induct
protect
immun
respons
report
sar
pandem
influenza
case
patient
infect
sftsv
also
mount
exagger
immun
respons
furthermor
cytokin
storm
hypercytokinemia
respons
signific
damag
bodi
tissu
organ
potenti
result
death
studi
proinflammatori
cytokin
ifnc
antiinflammatori
cytokin
elev
sftsvinfect
patient
level
dramat
higher
deceas
patient
similar
report
group
significantli
persist
elev
deceas
patient
level
trend
survivor
indic
possibl
use
biomark
monitor
progress
diseas
level
tnfa
similar
normal
healthi
donor
find
somewhat
differ
previou
report
show
tnfa
significantli
elev
sftsinfect
patient
especi
deceas
patient
clear
may
contribut
differ
time
sampl
collect
differ
assay
kit
potenti
factor
influenc
final
result
measur
conclus
current
studi
identifi
concurr
pattern
dynam
chang
viral
load
plt
key
serum
enzym
major
cell
subset
uniqu
cytokin
sft
patient
extend
understand
high
risk
emerg
viral
infect
discov
year
ago
find
involv
well
hladr
cell
sftsv
infect
lead
target
research
mechan
pathogenesi
come
futur
